Toll-like Receptor 9 (D2C9) Rabbit mAb





Orders:	877-616-CELL (2355) orders@cellsignal.com
Support:	877-678-TECH (8324)
Web:	info@cellsignal.com cellsignal.com

3 Trask Lane | Danvers | Massachusetts | 01923 | USA

For Research Use Only. Not for Use in Diagnostic Procedures.

Applications: W, IP	Reactivity: H	Sensitivity: Endogenous	MW (kDa): 130	Source/Isotype: Rabbit IgG	UniProt ID: #Q9NR96	Entrez-Gene Id: 54106
Product Usage Information		Application Western Blotting Immunoprecipitation			Dilution 1:1000 1:100	
Storage		Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 μg/ml BSA, 50% glycerol and less than 0.02% sodium azide. Store at –20°C. Do not aliquot the antibody.				
Specificity/Sen	sitivity			cognizes endogenous le n full-length isoforms of		
Source / Purific	ation	Monoclonal antibody is central ectodomain of l		nunizing animals with re in.	combinant protein	specific to the
Background		play a pivotal role in impathogens and mediat of NF-κB and subseque the IL-1 receptor family Toll/Interleukin-1 receptor cytoplasmic adapter pr (MyD88), MyD88-adapt inducing IFN-β (TRIF), a recruitment and activat IKK (8,11-14). Activation inactive state by seque TLR9 is highly expresses isoforms generated by bacterial DNA and stim family members that a to the ER in resting cell	nate immune resp e defense respons ent regulation of ir y share a conserve ptor (TIR) domain (oteins containing er-like/TIR-associa and Toll-receptor-a- tion of IRAK1 and n of IKK leads to th stering it in the cy ed in macrophages alternative splicin ulates NF-kB via the re localized to the s (20). Upon bindin	mily, named for the clos onses (1-4). TLRs recogn es (5-7). Triggering of th nmune and inflammator d stretch of approximator 1). Upon activation, TLRs TIR domains, including r ited protein (MAL/TIRAP ssociated molecule (TRA RAK4, which form a con te degradation of IKB, whi toplasm. c, dendritic cells, and B ly g (15,16). TLR9 binds to the MyD88 adaptor prote plasma membrane, TLR to CpG DNA, TLR9 is p ments where it binds My	ize conserved moti e TLR pathway lead ry genes (4). The TL ely 200 amino acides associate with a n myeloid differentian), TIR domain-conta M) (8-10). This asso nplex with TRAF6 to hich normally main rmphocytes, and in unmethylated CpG in (17-19). In contra 9 is an intracellular proteolytically proce	fs found in various ds to the activation Rs and members of the members of the member of tion factor 88 aning adapter- ociation leads to the o activate TAK1 and tains NF-κB in an humans has five motifs present on ast to most TLR receptor localized essed and
Background Re	eferences	1. Akira, S. (2003) <i>J Biol</i> 2. Beutler, B. (2004) <i>Na</i> 3. Dunne, A. and O'Neil 4. Medzhitov, R. et al. (1 5. Schwandner, R. et al. (19 7. Alexopoulou, L. et al. 8. Zhang, F.X. et al. (199 9. Horng, T. et al. (2001 10. Oshiumi, H. et al. (2001 10. Oshiumi, H. et al. (201 11. Muzio, M. et al. (199 12. Wesche, H. et al. (201 13. Suzuki, N. et al. (2001) 15. Du, X. et al. (2000) <i>J</i> 16. Chuang, T.H. and U 17. Hemmi, H. et al. (201 18. Bauer, S. et al. (2001) 19. Takeshita, F. et al. (201	ture 430, 257-63. II, L.A. (2003) <i>Sci S</i> 1997) <i>Nature</i> 388, (1999) <i>J Biol Chen</i> 299) <i>Immunity</i> 11, (2001) <i>Nature</i> 411 29) <i>J Biol Chem</i> 274) <i>Nat Immunol</i> 2, 5 203) <i>Nat Immunol</i> 2, 5 203) <i>Nat Immunol</i> 2, 5 207) <i>Science</i> 278, 16 207) <i>Science</i> 278, 16 207) <i>Nature</i> 416, 75 <i>FEBS Lett</i> 467, 160 <i>Eur Cytokine Netw</i> levitch, R.J. (2000) 000) <i>Nature</i> 408, 74 1) <i>Proc Natl Acad</i> 5	TKE 2003, re3. 394-7. 1274, 17406-9. 443-51. 3, 732-8. 4, 7611-4. 335-41. /4, 161-7. 512-5. 37-47. 0-6. -4. 11, 362-71. Eur Cytokine Netw 11, 3 40-5. 5ci U S A 98, 9237-42.	72-8.	

	21. Park, B. et al. (2008) <i>Nat Immunol</i> 9, 1407-14. 22. Ewald, S.E. et al. (2008) <i>Nature</i> 456, 658-62. 23. Sepulveda, F.E. et al. (2009) <i>Immunity</i> 31, 737-48.		
Species Reactivity	Species reactivity is determined by testing in at least one approved application (e.g., western blot).		
Western Blot Buffer	IMPORTANT: For western blots, incubate membrane with diluted primary antibody in 5% w/v BSA, 1X TBS, 0.1% Tween® 20 at 4°C with gentle shaking, overnight.		
Applications Key	W: Western Blotting IP: Immunoprecipitation		
Cross-Reactivity Key	H: Human		
Trademarks and Patents	Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.		
	All other trademarks are the property of their respective owners. Visit cellsignal.com/trademarks for more information.		
Limited Uses	Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.		
	Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.		

20. Latz, E. et al. (2004) Nat Immunol 5, 190-8.